IMI 2 - JTI Innovative Medicines Initiative
The Public-Private Partnership "Innovative Medicines Initiative" was established at the beginning of the 7th Framework Programme as a Joint Technology Initiative (JTI) and will continue to run for the duration of Horizon 2020 and until 2024. The aim of IMI2 is to pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe’s pharmaceutical industry.
IMI2 has identified four priority areas, in which joint research projects of industry and research institutions can get financial support:
- Target validation and biomarkers research (efficacy and safety) (Axis 1)
- Adoption of innovative clinical trial paradigms (Axis 2)
- Innovative Medicines (Axis 3)
- Patient tailored adherence programmes (Axis 4)
The JTI is implemented by the "Innovative Medicines Initiative 2" (IMI2 JU). Members of this Public-Private Partnership with its registered office in Brussels, is the European Union, represented by the European Commission and the pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
On July 10, 2013, the European Commission has issued the proposal for the continued implementation of the IMI2 JU for the period 2014-2024. This proposal is currently being discussed in the European Parliament and the Council is expected to decide on it and issue the corresponding regulation in early 2014.
Based on a Strategic Resarch Agenda the JU will implement a ten-year programme for research funding, that will be open for all EU member states and associated states. According to the Commission proposal the total funding will amount to EUR 3.45 billion, of which EUR 1.73 million comes from Horizon 2020 and EUR 1.4 billion as a contribution in kind from the participating EFPIA enterprises. In addition other life science industries may contribute a further amount of money if they decide to join IMI2 as a member or as partners in individual projects.
Until the renewal of the contract, the JU is currently running based on the previous and still valid regulation and will publish its 11th Call in December 2013.